Perceptive Advisors’s BridgeBio Pharma BBIO Stock Holding History

Perceptive Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,215,346	Closed	-$30.8M	–	110
2024 Q2	$30.8M	Sell	1,215,346 -196,687	-14%	-$5.38M	0.74%	41
2024 Q1	$43.7M	Sell	1,412,033 -336,900	-19%	-$11.5M	0.76%	43
2023 Q4	$70.6M	Hold	1,748,933	–	–	1.58%	19
2023 Q3	$46.1M	Hold	1,748,933	–	–	1.54%	19
2023 Q2	$30.1M	Sell	1,748,933 -158,100	-8%	-$2.38M	0.87%	37
2023 Q1	$31.6M	Buy	1,907,033 +210,000	+12%	+$2.45M	0.93%	36
2022 Q4	$12.9M	Hold	1,697,033	–	–	0.36%	56
2022 Q3	$16.9M	Hold	1,697,033	–	–	0.49%	50
2022 Q2	$15.4M	Sell	1,697,033 -2,142,347	-56%	-$17.9M	0.48%	46
2022 Q1	$39M	Sell	3,839,380 -3,289,375	-46%	-$33.8M	0.78%	35
2021 Q4	$119M	Sell	7,128,755 -628,173	-8%	-$26.6M	1.83%	14
2021 Q3	$364M	Hold	7,756,928	–	–	5.28%	3
2021 Q2	$473M	Hold	7,756,928	–	–	6.14%	2
2021 Q1	$478M	Buy	7,756,928 +1,050,660	+16%	+$68.7M	6.04%	2
2020 Q4	$477M	Hold	6,706,268	–	–	5.12%	3
2020 Q3	$252M	Hold	6,706,268	–	–	3.67%	6
2020 Q2	$219M	Hold	6,706,268	–	–	3.54%	8
2020 Q1	$194M	Hold	6,706,268	–	–	5.07%	6
2019 Q4	$142M	Hold	6,706,268	–	–	2.83%	10
2019 Q3	$144M	Hold	6,706,268	–	–	3.88%	6
2019 Q2	$181M	Buy	+6,706,268	New	+$183M	4.15%	7

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's BBIO Position: Q3 2024 in Review

Perceptive Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 1,215,346 shares — an estimated $30.8M sold.

Perceptive Advisors first reported a position in BBIO in Q2 2019 and held it in 21 quarters. The position peaked at $478M in Q1 2021. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

Perceptive Advisors reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
Perceptive Advisors sold 1,215,346 BridgeBio Pharma shares in Q3 2024, an estimated $30.8M.
Perceptive Advisors first reported a position in BridgeBio Pharma in Q2 2019 and held it in 21 quarters.
Perceptive Advisors's BridgeBio Pharma position peaked at $478M in Q1 2021.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.